Market drivers that vary geographically account for some big differences in the distribution of the coronary stent market across the currently available stent types, and these differences will continue when bioabsorbable stents (and others) are introduced to the market over the next few years. The local market forces dictating these differences include: Regulatory timelines in [...]
My posts on advanced medical technology, drawing frequently from our market reports, are worth emphasizing for their global perspective. Some two decades ago, it became apparent to me that that the global market perspective is not reserved for big, multi-national companies and their global presence. My understanding of this came about from the experience of [...]
The coronary stent market has represented a marvelous opportunity for many medical technology companies, but even though it is a huge market now, and has generated enormous cash flow for early entrants, it runs significant risk for current manufacturers as well as those seeking to gain share of this multi-billion dollar global market. The reason [...]
In the $7 billion+ worldwide market for drug-eluting coronary stents, a consistent theme is now the myriad challenge to existing players from the host of emerging competitors, particularly since the advent of drug-eluting stents (DES). Although not so long ago the DES market was monopolized by J&J/Cordis, then split and controlled by J&J and Boston [...]
The evolution of the coronary stent market, like most medical device markets, has been driven by manufacturers focused on expanding the use of coronary stents into new caseload as well as penetrating the market shares of competitors. Clinicians, for their turn as gatekeepers in this effort, are guided in the adoption of stent technologies [...]
Perhaps in no other market is it more imperative for current competitors to keep their eyes on the horizon than in the market for treatments of coronary artery disease. As I have ranted previously (search "coronary artery disease" on this blog), alternative treatments stretch from device to surgery to biotech and options too difficult to [...]
Below is an excerpt from "Worldwide Wound Management Market, 2008-2017," published by MedMarket Diligence. A wide range of regulatory approval conditions are applied to wound management products. The decision about regulatory classification for a given wound management product lies with the regulatory authority of the country in which the product is to be marketed and [...]
With medtech investments in July and August each at over $400 million, I had hopes (expectations?) that September would continue the trend, but through Sept. 30, medtech financings for the month totaled "only" $328 million. Of course, this is still a healthy amount, especially considering that September investment tends to be lower on a relative [...]
The identification of those atherosclerotic plaques most likely to result in heart attack when they embolize is a goal with multiple benefits. These "vulnerable plaques", if effectively picked up via technques like intravascular ultrasound (see below), can become the focus of prevention and a more precise target of intervention. The alternative is, at least in [...]
Results from the SPIRIT IV trial, comparing safety and efficacy of everolimus-eluting and Paclitaxel-eluting stents in treatment of coronary lesions, were described today (see link), below: SAN FRANCISCO, CA SEPTEMBER 23, 2009 Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced [...]
Contact:
